2024预见ASCO｜靶向治疗、免疫治疗、ADC药物、双特异性抗体大年夜显身手哪些是你的picks？_摘要_突变

Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.

可切除EGFR突变II-IIIA期NSCLC接管12个月或6个月的埃克替尼赞助治疗比拟赞助化疗后不雅观察：一项随机III期试验（ICTAN，GASTO1002）

讲者：王思愚教授（中山大学肿瘤防治中央）

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

ADAURA试验中奥希替尼赞助治疗可切除EGFR突变IB-IIIA期NSCLC患者的分子残留病灶（MRD）剖析

讲者：Tom John（Peter MacCallum Cancer Centre）

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.

Amivantamab联合lazertinib比拟奥希替尼治疗一线伴高危疾病生物标志物的EGFR突变晚期NSCLC：III期MARIPOSA研究的二次剖析

讲者：Enriqueta Felip（Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology）

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

皮下注amivantamab比拟静脉注射amivantamab联合lazertinib治疗难治性EGFR突变的晚期NSCLC：环球III期随机对照PALOMA-3试验的紧张结果，包括总生存期（OS）

讲者：Natasha B. Leighl（Princess Margaret Cancer Centre）

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.

依沃西单抗联合化疗治疗接管EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者：一项随机、双盲、多中央、III期试验（HARMONi-A）

讲者：张力教授（中山大学肿瘤防治中央）

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.

Telisotuzumab vedotin单药治疗既往接管过治疗的c-Met过表达非鳞状EGFR野生型晚期NSCLC患者：LUMINOSITY试验的紧张剖析

讲者：David Ross Camidge（University of Colorado Cancer Center）

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.

舒沃替尼治疗含铂化疗失落败的EGFR exon 20ins NSCLC：一项国际多中央注册临床研究，WU-KONG1研究的初步剖析结果

讲者：杨志新教授（中国国立台湾大学肿瘤中央医院）

Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.

amivantamab联合lazertinib治疗非范例EGFR突变的晚期NSCLC：CHRYSALIS-2研究结果

讲者：Byoung Chul Cho（Yonsei Cancer Center）

A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.

amivantamab联合lazertinib治疗EGFR突变型肺癌和活动性中枢神经系统疾病患者的II期研究

讲者：Helena Alexandra Yu（Memorial Sloan Kettering Cancer Center）

Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.

奥希替尼联合巩固性立体定向溶解放疗（SABR）治疗晚期EGFR突变NSCLC的安全性和有效性：多中央II期试验结果

讲者：Sawsan Rashdan（UT Southwestern）

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

aurora激酶A（AURKA）抑制剂VIC-1911联合奥希替尼治疗TKI耐药、EGFR突变NSCLC的I期临床试验

讲者：Shen Zhao（中山大学肿瘤防治中央）

EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis.

EGFR-TKI作为EGFR敏感突变NSCLC患者的新赞助治疗：一项回顾性现实天下剖析

讲者：Sangtian Liu（广州医科大学第一附属医院）

Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).

阿美替尼联合或不联合化疗赞助治疗完备切除后II-IIIA期NSCLC的疗效和安全性：第一个第三代EGFR-TKI比拟化疗的III期临床研究（APEX）

讲者：Feng Tan（中国医学科学院北京协和医学院肿瘤医院）

Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.

Mefatinib作为EGFR突变阳性NSCLC的一线治疗：III期疗效和生物标志物研究

讲者：Jia Yu（上海市肺科医院）

Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.

吉非替尼联合贝伐珠单抗和化疗一线治疗EGFR突变的晚期非鳞状NSCLC的Ib期临床研究

讲者：熊艳娟教授（天津医科大学肿瘤医院）

Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.

舒沃替尼治疗EGFR外显子20插入突变的NSCLC患者血浆ctDNA生物标志物研究

讲者：Mengzhao Wang

High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.

高剂量伏美替尼治疗EGFR突变NSCLC和软脑膜转移患者：一项真实天下的研究

讲者：陈海洋教授（河南省肿瘤医院）

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.

Amivantamab联合化疗比拟化疗作为EGFR外显子20插入突变晚期NSCLC的一线治疗：PAPILLON研究中国亚组剖析

讲者：唐可京教授（中山大学附属第一医院）

TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations

TOP研究：一项III期、多中央、随机对照研究，奥希替尼联合卡铂和培美曲塞比拟奥希替尼单药治疗伴有EGFR和TP53突变的晚期非鳞状NSCLC患者的疗效

讲者：杨云鹏教授（中山大学肿瘤防治中央）

Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.

阿来替尼赞助治疗与化疗在切除的ALK阳性NSCLC患者中的康健干系生活质量（HRQoL）结果比拟：数据来自ALINA

讲者：Makoto Nishio（Cancer Institute Hospital of Japanese Foundation for Cancer Research）

Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).

在不可切除的局部晚期ALK阳性NSCLC中，比较巩固性ALK-TKI与度伐利尤单抗或放化疗（CRT）后不雅观察的环球回顾性研究

讲者：Ritujith Jayakrishnan（Yale New Haven Hospital）

Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

CROWN研究5年无进展生存（PFS）率和安全性结果公布：比较洛拉替尼与克唑替尼在ALK阳性晚期NSCLC初治患者中的疗效与安全性

讲者：Benjamin J. Solomon（Peter MacCallum Cancer Centre）

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

III期KRYSTAL-12研究：adagrasib比拟多西他赛治疗经治的KRAS G12C突变晚期/转移性NSCLC患者

讲者：莫树锦教授（喷鼻香港中文大学）

Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.

第二代KRAS G12C抑制剂（G12Ci）olomorasib（LY3537982）联合帕博利珠单抗治疗KRAS G12C突变晚期NSCLC患者的疗效和安全性

讲者：Timothy F. Burns（University of Pittsburgh Medical Center Hillman Cancer Center）

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

II期KROCUS研究：fulzerasib（GFH925）联合西妥昔单抗治疗未经治的晚期KRAS G12C突变NSCLC患者的疗效和安全性

讲者：Vanesa Gregorc（Candiolo Cancer Institute）

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Sotorasib 联合卡铂和培美曲塞治疗KRAS G12C晚期NSCLC：国际CodeBreaK 101试验的最新剖析

讲者：Bob T. Li（Memorial Sloan Kettering Cancer Center）

Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.

ifebemtinib（IN10018）联合D-1553治疗KRAS G12C突变NSCLC的安全性和有效性：Ib/II期研究的结果

讲者：Zaiqi Wang

Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.

洛拉替尼治疗TKI未经治的晚期ROS1阳性NSCLC：一项多中央、开放标签、单臂、II期试验

讲者：Beung Chul AHN（National Cancer Center）

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

taletrectinib治疗晚期或转移性ROS1阳性NSCLC患者的疗效和安全性：II期TRUST-I研究

讲者：李玮教授（上海市肺科医院）

Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.

伯瑞替尼治疗MET14号外显子跳跃突变晚期NSCLC的疗效和安全性：KUNPENG研究2.5年随访结果

讲者：Jin-Ji Yan

Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.

HER2-TKI zongertinib（BI 1810631）在HER2突变阳性实体瘤患者（pts）中的Ia/Ib期试验：Beamion LUNG-1研究的Ia期数据更新，包括无进展生存期

讲者：John Heymach（The University of Texas MD Anderson Cancer Center）

Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.

厄达替尼在一项开放标签、单臂、II期RAGNAR试验中对NSCLC成年患者和预先指定的成纤维细胞成长因子受体突变的患者的疗效和安全性

讲者：Martin H. Schuler（West German Cancer Center）

An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).

ATR抑制剂SC0245联合伊立替康治疗复发难治性ES-SCLC的开放标签、多中央、Ib/II期研究

讲者：虞永峰教授（上海市胸科医院）

MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.

MEK抑制剂联合RTK抑制剂（曲美替尼联合安罗替尼）治疗非G12C KRAS突变型NSCLC：一种新策略

讲者：韩宝惠教授（上海市胸科医院）

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

ADRIATIC：度伐利尤单抗作为局限期小细胞肺癌（LS-SCLC）患者的巩固治疗

讲者：David R. Spigel（Sarah Cannon Research Institute）

BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

III期随机对照BEAT-SC研究：比较贝伐珠单抗或安慰剂联合阿替利珠单抗和铂类化疗治疗广泛期小细胞肺癌（ES-SCLC）患者的疗效与安全性

讲者：Yuichiro Ohe（National Cancer Center Hospital）

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.

III期可切除NSCLC患者围手术期运用纳武利尤单抗的淋巴结状态临床结果：III期CheckMate 77T研究的结果

讲者：Tina Cascone（The University of Texas MD Anderson Cancer Center）

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).

一项评估局部晚期NSCLC新赞助化疗联合纳武利尤单抗和同步放化疗后纳武利尤单抗巩固治疗的II期随机试验（GASTO-1091）

讲者：刘慧教授（中山大学肿瘤防治中央）

Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.

新赞助纳武利尤单抗联合化疗比拟单独化疗治疗可切除NSCLC：CheckMate 816研究4年数据更新

讲者：Jonathan Spicer（McGill University Health Centre）

Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.

围手术期度伐利尤单抗治疗可切除NSCLC和基线N2淋巴结受累（N2 R-NSCLC）患者的结局：AEGEAN的探索性亚组剖析

讲者：John Heymach（The University of Texas MD Anderson Cancer Center）

Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).

围手术期帕博利珠单抗治疗早期NSCLC的随机，双盲III期KEYNOTE-671研究的康健干系生活质量（HRQoL）结果

讲者：Marina Chiara Garassino（Fondazione IRCCS Istituto Nazionale dei Tumori）

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.

阿得贝利单抗联合化疗和序贯胸部放疗作为ES-SCLC的一线治疗的总生存期（OS）

讲者：陈大卫教授（山东第一医科大学附属肿瘤医院）

A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).

替雷利珠单抗（TIS）和化疗新赞助治疗可切除的IIIA/IIIB期NSCLC的II期研究

讲者：Ting Wang

Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.

PD-1抗体联合铂类双联化疗勾引治疗局部晚期NSCLC：一项随机对照，开放标签的II期临床试验

讲者：Suyu Wang（同济大学附属上海市肺科医院）

Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.

随机II期neoSCORE试验的最终生存结果和探索性生物标志物剖析：信迪利单抗联合化疗新赞助治疗可切除的癌症两个周期与三个周期的比较

讲者：邱福铭教授（浙江大学医学院附属第二医院）

Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.

大分割放疗联合帕博利珠单抗和化疗新赞助治疗可切除的NSCLC：一项Ib期研究

讲者：丁乃昕教授（南京医科大学附属肿瘤医院）

The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer.

勾引化学免疫治疗在不可切除的III期NSCLC中的安全性和有效性

讲者：Min Tang（中国医学科学院老年医学研究所国家老年医学中央）

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).

在局部晚期NSCLC中，新赞助化疗联合替雷利珠单抗±贝伐珠单抗，然后进行大分割放疗，同时化疗和巩固免疫治疗的II期双行列步队研究（GASTO-1086）

讲者：邱波教授（中山大学肿瘤防治中央）

Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.

新赞助化学免疫疗法治疗不可切除的III期NSCLC后序贯手术切除的疗效和手术安全性

讲者：Yana Qi（山东省肿瘤医院）

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.

PD-L1抑制剂与PD-1抑制剂用于ES-SCLC的一线治疗：方向评分匹配研究

讲者：田亚如教授（山东省肿瘤医院）

Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study

Tifcemalimab联合特瑞普利单抗和化疗作为ES-SCLC的一线治疗：Ib/II期开放标签研究

讲者：虞永峰教授（上海市胸科医院）

Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.

PD-L1单抗联合化疗治疗ES-SCLC的III期临床试验结果

讲者：陆舜教授（上海交通大学附属胸科医院）

A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.

LS-SCLC同步放化疗后特瑞普利单抗巩固或不雅观察的随机II期研究

讲者：邱波教授（中山大学肿瘤防治中央）

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.

斯鲁利单抗与安慰剂联合化疗作为ES-SCLC一线治疗的比较：国际ASTRUM-005III期研究的延伸随访结果和患者报告结果

讲者：程颖教授（吉林省肿瘤医院）

Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study.

新赞助特瑞普利单抗联合化疗治疗EGFR突变的可切除II-IIIB期非鳞状NSCLC：一项多中央、多行列步队、探索性研究

讲者：Sida Cheng（北京大学公民医院）

A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as a first-line treatment for oligo-metastatic extensive-stage small-cell lung cancer.

阿得贝利单抗联合化疗和同步放疗作为寡转移性ES-SCLC的一线治疗的II期探索性试验

讲者：董忠谊教授（南方医科大学南方医院放射肿瘤科）

Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.

支气管动脉化疗栓塞（BACE）联合替雷利珠单抗治疗NSCLC的疗效和安全性：II期研究

讲者：段旭华教授（郑州大学第一附属医院）

Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

戈沙妥珠单抗（SG）比拟多西他赛（doc）治疗既往接管过铂类化疗（PT）和PD(L)-1抑制剂（IO）治疗的转移性NSCLC患者：III期EVOKE-01研究的初步结果

讲者：Luis G. Paz-Ares（Hospital Universitario 12 De Octubre）

ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.

II期ICARUS-LUG01研究：通过连续组织活检和生物标志物剖析预测Dato-DXd在经治的晚期NSCLC患者中的治疗结果

讲者：David Planchard（Gustave Roussy）

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.

II期OptiTROP-Lung01研究：Sacituzumab tirumotecan（SKB264/MK-2870）联合KL-A167（抗PD-L1）作为中晚期NSCLC患者的一线治疗

讲者：方文峰教授（中山大学肿瘤防治中央）

Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).

一种研究性ADC sigvotatug vedotin在NSCLC中的疗效和安全性：I期SGNB6A-001结果更新

讲者：Solange Peters（Centre Hospitalier Universitaire Vaudoi）

ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).

ARTEMIS-001:HS-20093在复发性SCLC患者中的Ia/b期研究数据

讲者：王洁教授（中国医学科学院肿瘤医院）

Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.

Dato-DXd在中国晚期或转移性NSCLC患者中的运用：I/II期TROPION-PanTumor02研究结果

讲者：Yuping Sun

A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).

telisotuzumab vedotin与多西紫杉醇治疗c-Met过表达、EGFR野生型、局部晚期/转移性非鳞状NSCLC（TeliMET NSCLC-01）患者的III期环球研究

讲者：陆舜教授（上海交通大学附属胸科医院）

DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis.

DeLLphi-301:Tarlatamab治疗SCLC的II期临床试验——通过脑转移剖析疗效和安全性

讲者：Anne-Marie C. Dingemans（Erasmus MC Cancer Institute）

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.

新赞助SHR-1701在不可切除的III期NSCLC中有或没有化疗：观点验证II期试验（TRAILBLAZER）中手术转换结果的有效性，安全性和可行性

讲者：吴一龙教授（广东省公民医院）

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.

评估PM8002（一种靶向PD-L1和VEGF-A的双特异性抗体）作为晚期NSCLC患者的单一疗法的安全性和有效性的Ib/IIa期试验

讲者：吴春娇教授（吉林省肿瘤医院）

Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)

EGFR/c-MET双特异性抗体MCLA-129在晚期NSCLC中的疗效和安全性

讲者：王洁教授（中国医学科学院肿瘤医院）

Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.

在晚期肺癌患者中通过远程医疗供应的早期姑息治疗与亲自供应的早期姑息治疗的疗效比较试验

讲者：Joseph A. Greer（Massachusetts General Hospital）

Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.

台湾地区对付重度吸烟以及有肺癌家族史的非吸烟人群肺癌早期检测操持

讲者：Pan-Chyr Yang（台湾大学医学院）

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).

NRG-LU002：坚持性全身治疗比拟局部巩固治疗（LCT）联合坚持性全身治疗局限转移NSCLC的随机II/III期临床试验

讲者：Puneeth Iyengar（Memorial Sloan Kettering Cancer Center）

ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months.

ctDNA肺检测：12个月时切除的早期NSCLC的ctDNA结果

讲者：Sam Khan（Princess Margaret Cancer Centre）

Investigation of the role of personalized molecular residual disease in the assessment of high-risk non-small cell lung cancer (NSCLC) post-operation.cancer: A systematic review and meta-analysis of randomized clinical trials.

个体化MRD在高危NSCLC术后评估中的浸染研究

讲者：Yu-Heng Zhou（中山大学肿瘤防治中央）

Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.

安罗替尼联合多西紫杉醇治疗晚期NSCLC的免疫治疗进展：两项随机试验的汇总剖析

讲者：Lin Wu